Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Assets (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Other Non-Current Assets data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, changed 0.0%, while the annual FY2025 figure was $1.6 million, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $1.6 million in Q4 2025 per OCUL's latest filing, roughly flat from $1.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 million in Q1 2021 and bottomed at $1.6 million in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $1.7 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: changed 0.0% in 2021, then decreased 8.5% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then fell by 8.5% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.